Einige Inhalte dieser Anwendung sind momentan nicht verfügbar.
Wenn diese Situation weiterhin besteht, kontaktieren Sie uns bitte unterFeedback&Kontakt
1. (WO2019067844) ENDOTHELIAL FACILITATION IN NEURODEGENERATIVE DISEASES BY CEREBRAL BLOOD FLOW ENHANCEMENT
Anmerkung: Text basiert auf automatischer optischer Zeichenerkennung (OCR). Verwenden Sie bitte aus rechtlichen Gründen die PDF-Version.

A method, comprising:

a) providing;

i) a patient exhibiting at least one symptom of a neurodegenerative disease; and

ii) a pharmaceutical composition comprising a statin; and

b) administering said pharmaceutical composition to said patient under conditions such that said at least one symptom is reduced.

The method of Claim 1, wherein said pharmaceutical composition further comprises a nitric oxide synthase substrate.

The method of Claim 1, wherein said pharmaceutical composition further comprises a bi opteri n compoun d .

The method of Claim 1, wherein said pharmaceutical composition comprises a combination of said statin and said nitric oxide synthase substrate.

The method of Claim 1, wherein said pharmaceutical composition comprises a combination of said statin, said nitric oxide synthase substrate and said biopterin compound.

The method of Claim 1, wherein said statin pharmaceutical composition is administered for a first time period.

The method of Claim 4, wherein said combined statin/nitric oxide substrate

pharmaceutical composition is administered for a second time period.

8. The method of Claim 5, wherein said combined statin/nitric oxide substrate/biopterin compound composition is administered for a third time period.

9, The method of Claim 6, wherein said first time period precedes said second time period.

10. The method of Claim 7, wherein said second time period precedes said third time period,

11. The method of Claim 6, wherein said first time period is one month.

12. The method of Claim 7, wherein said second time period is one month.

13. The method of Claim 8, wherein said third time period is two months.

14. The method of Claim 1, wherein said statin is selected from the group consisting of

atorvastatin, fluvastatin, lovastatin, pravastatin, pravastatin, rosuvastatin and simvastatin.

15. The method of Claim 2, wherein said nitric oxide substrate is selected from the group consisting of L-arginine, L-citruliine and NG-hydroxy-L-arginine.

16. The method of Claim 3, wherein said biopterin is selected from the group consisting of tetrahydrobiopterin and dihydrobipterin.

17. The method of Claim 1, wherein said at least one symptom comprises reduced cognitive function.

18. The method of Claim 1, wherein said at least one symptom comprises cerebral atrophy.

19. The method of Claim 1, wherein said at least one symptom comprises reduced brain

microvascular endothelial function.

The method of Claim 4, said combined statin/nitric oxide substrate pharmaceutical compound is synergistic as compared to said statin pharmaceutical compound.

The method of Claim 5, wherein said combined statin/nitric oxide substrate/biopterin compound pharmaceutical compound is synergistic as compared to said statin pharmaceutical compound.

The method of Claim 5, wherein said combined statin/nitric oxide substrate/biopterin compound pharmaceutical compound is synergistic as compared to said combined statin/nitric oxide substrate pharmaceutical compound.

The method of Claim 1, wherein said neurodegenerative disease is Alzheimer's disease.

The method of Claim 1, wherein said neurodegenerative disease is dementia.

The method of Claim 1 , wherein said neurodegenerative disease is selected from the group consisting of Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson's disease.

The method of Claim 1, wherein said method further compri ses a step of improving brain microvascular and endothelial function.

The method of Claim 1, wherein said method further comprises a step of stimulating brain endothelial nitric oxide synthase activity.

The method of Claim 1, wherein said neurodegenerative disease comprises an early stage Alzheimer's disease.

The method of Claim 1, wherein said neurodegenerative disease comprises a mild cognitive impairment.

The method of Claim 27, wherein said stimulated brain endothelial nitric oxide synthase activity improves brain microvascular endothelial function.